EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements
- 8 December 2005
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 45 (4) , 349-356
- https://doi.org/10.1002/gcc.20295
Abstract
In contrast to the well‐documented involvement of EVI1 in various 3q26 aberrations, the transcriptional status of EVI1 in rare recurrent or sporadic 3q26 chromosomal defects has remained largely unexplored. Moreover, in a recent report, the association between 3q26 alterations in myeloid proliferations and ectopic EVI1 expression was questioned. Therefore, we performed a detailed physical mapping of 3q26 breakpoints using a 1.3‐Mb tiling path BAC contig covering the EVI1 locus and a carefully designed quantification of both EVI1 and MDS/EVI1 transcripts in 30 hematological malignancies displaying 3q26 aberrations. Cases included well‐known rare, recurring chromosomal aberrations such as t(3;17)(q26;q22), t(2;3)(p21–22;q26), and t(3;6)(q26;q25), as well as 10 new sporadic cases. Extensive 3q26 breakpoint mapping allowed unequivocal and sensitive FISH detection of EVI1 rearrangements on both metaphases and interphase nuclei. Real‐time quantitative PCR analyses indicated that typically both MDS1/EVI1 and EVI1, but not MDS1, were expressed in these malignancies, with EVI1 the primary transcript. In conclusion, we have demonstrated EVI1 involvement in numerous novel sporadic and recurrent 3q26 rearrangements. Our results underscore the feasibility of FISH as an adjunct to PCR for the identification of EVI1 deranged leukemias and identified EVI1 as the principal transcript expressed in these malignancies.Keywords
Funding Information
- Fund for Scientific Research of Flanders (G.0310.01)
- Fund for Scientific Research of Flanders
- Institute for the Promotion of Innovation by Science & Technology (IWT), Flanders
This publication has 29 references indexed in Scilit:
- Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemiaGenes, Chromosomes and Cancer, 2002
- Localization of the 17q breakpoint of a constitutional 1;17 translocation in a patient with neuroblastoma within a 25‐kb segment located between the ACCN1 and TLK2 genes and near the distal breakpoints of two microdeletions in neurofibromatosis type 1 patientsGenes, Chromosomes and Cancer, 2002
- Structural rearrangements of chromosome 3 in 57 patients with acute myeloid leukemia: clinical, hematological and cytogenetic featuresThe Hematology Journal, 2002
- Interphase fluorescence in situ hybridization assay for the detection of 3q21 rearrangements in myeloid malignanciesGenes, Chromosomes and Cancer, 2001
- MDS1/EVI1 enhances TGF-β1 signaling and strengthens its growth-inhibitory effect, but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-β1Leukemia, 1999
- Identification of Translocational Breakpoints within the Intron Region before the Last Coding Exon (Exon 12) of theEVI1Gene in Two Cases of CML-BC with Inv(3)(q21q26)Genomics, 1997
- The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivatorLeukemia, 1997
- t(2;3)(p23;q26) in a patient with AML M2British Journal of Haematology, 1996
- Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell linesCell, 1988
- Translocation t(3;17)(q26;q22): A marker of acute disease in myeloproliferative disorders?Cancer Genetics and Cytogenetics, 1984